PDCD1 and neoplasm: Briefly, cohorts of LLC-OVA tumor-bearing mice were administered monotherapies consisting of anti-PD-1 antibody, MTR-OralGem, MTD-Gem or anti-PD-1 and MTR-OralGem combination therapy (Supplementary Methods S.M.6, experimental protocol Figure 7A).